- Home
- PSTL vs ORKA Comparison
PSTL vs ORKA Comparison
Compare PSTL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- ORKA
- Stock Information
- Founded
- PSTL 2018
- ORKA 2004
- Country
- PSTL United States
- ORKA United States
- Employees
- PSTL N/A
- ORKA N/A
- Industry
- PSTL Real Estate Investment Trusts
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PSTL Real Estate
- ORKA Health Care
- Exchange
- PSTL Nasdaq
- ORKA Nasdaq
- Market Cap
- PSTL 322.0M
- ORKA 354.2M
- IPO Year
- PSTL 2019
- ORKA N/A
- Fundamental
- Price
- PSTL $14.09
- ORKA $11.94
- Analyst Decision
- PSTL Strong Buy
- ORKA Strong Buy
- Analyst Count
- PSTL 1
- ORKA 8
- Target Price
- PSTL $16.50
- ORKA $39.71
- AVG Volume (30 Days)
- PSTL 190.9K
- ORKA 146.0K
- Earning Date
- PSTL 04-30-2025
- ORKA 05-14-2025
- Dividend Yield
- PSTL 6.89%
- ORKA N/A
- EPS Growth
- PSTL 176.54
- ORKA N/A
- EPS
- PSTL 0.28
- ORKA N/A
- Revenue
- PSTL $81,235,000.00
- ORKA N/A
- Revenue This Year
- PSTL $16.20
- ORKA N/A
- Revenue Next Year
- PSTL $10.62
- ORKA N/A
- P/E Ratio
- PSTL $49.77
- ORKA N/A
- Revenue Growth
- PSTL 23.36
- ORKA N/A
- 52 Week Low
- PSTL $12.26
- ORKA $5.49
- 52 Week High
- PSTL $15.15
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- PSTL 69.14
- ORKA N/A
- Support Level
- PSTL $12.95
- ORKA N/A
- Resistance Level
- PSTL $14.16
- ORKA N/A
- Average True Range (ATR)
- PSTL 0.28
- ORKA 0.00
- MACD
- PSTL 0.12
- ORKA 0.00
- Stochastic Oscillator
- PSTL 95.45
- ORKA 0.00
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.